Core Viewpoint - Oruka Therapeutics has announced a PIPE financing agreement expected to generate approximately $180 million in gross proceeds to support its development of novel biologics for chronic skin diseases, particularly plaque psoriasis [1][3]. Financing Details - The PIPE financing involves the sale of 10,933,405 shares of common stock at $15.00 per share and pre-funded warrants for 1,066,666 shares at $14.999 each, with an exercise price of $0.001 per share [2]. - The transaction is anticipated to close around September 19, 2025, pending customary closing conditions [2]. Use of Proceeds - The net proceeds from the PIPE financing will be utilized for research and development, general corporate expenses, and working capital needs, with expectations that current cash will fund operations for at least one year following key clinical data readouts in 2027 [3]. Investor Participation - The PIPE financing was led by Viking Global Investors and included participation from various notable investors such as Affinity Healthcare Fund, Blackstone Multi-Asset Investing, and others [1][4]. Company Overview - Oruka Therapeutics focuses on developing biologics aimed at setting new treatment standards for chronic skin diseases, with a mission to provide significant relief to patients suffering from conditions like plaque psoriasis [7].

Core Insights - Oruka Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1][2] - The company aims to provide patients with significant freedom from chronic skin conditions by achieving high rates of complete disease clearance with infrequent dosing, potentially as little as once or twice a year [2] - Oruka is advancing a proprietary portfolio of antibodies engineered to target the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [2] Event Announcement - Oruka will present at the Jefferies Global Health Care Conference in New York on June 4, 2025, at 12:50 PM ET [1] - A webcast and replay of the presentation will be available on the Oruka investor events website [1] Company Information - Oruka Therapeutics is committed to setting a new standard in the treatment of chronic skin diseases through innovative biologics [2] - The company’s mission emphasizes achieving high rates of disease clearance for patients suffering from conditions like plaque psoriasis [2]

Core Insights - Oruka Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis [1][2] - The company aims to provide patients with significant freedom from chronic skin conditions by achieving high rates of complete disease clearance with infrequent dosing, potentially as little as once or twice a year [2] Company Overview - Oruka Therapeutics is advancing a proprietary portfolio of potentially best-in-class antibodies engineered by Paragon Therapeutics, targeting the core mechanisms of plaque psoriasis and other dermatologic and inflammatory diseases [2] - The company is set to present at the Bank of America Securities 2025 Health Care Conference on May 13th, 2025, at 3:55 PM PT, indicating its active engagement with the investment community [1]